Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eIF4E inhibitor

- PMLiVE

UK agrees further COVID-19 vaccine deals with Pfizer/BioNTech, Valneva

Government has already agreed similar deal with AstraZeneca

- PMLiVE

FDA fast-tracks Pfizer/BioNTech’s COVID-19 vaccine candidates

Two investigational candidates granted accelerated review

- PMLiVE

Porter Novelli wins first Best Use of Data Visualisation Award at Communiqué 2020

The winning initiative for this new category was created by Pfizer Oncology

- PMLiVE

IFPMA launches AMR Action Fund to tackle antimicrobial resistance

Pharma and health organisations unite to address public health threat

- PMLiVE

Pfizer jumps on early data from BioNTech-partnered COVID-19 vaccine study

Preliminary data demonstrates promising immunogenicity

Impetus Digital Fireside Chat with Eddie Power from Pfizer

Eddie Power, Vice President of North America Medical Affairs, Hospital Business at Pfizer, discusses a range of topics, including the effects of COVID-19 on the way Medical Affairs teams work and...

Impetus Digital

- PMLiVE

COVID-19 delays Pfizer, Mylan’s generics merger and spin-out

Fallout from pandemic continues to affect business in myriad ways

- PMLiVE

Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win

New-generation shot could protect franchise from rival Merck & Co

- PMLiVE

Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer

Checkpoint inhibitor unlikely to improve progression-free survival

- PMLiVE

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

EU approval will help drug achieve blockbuster status

- PMLiVE

NICE turns down Keytruda/Inlyta combo for kidney cancer

Cost-effectiveness agency says the long-term benefit is uncertain

- PMLiVE

GSK considers more divestments to help R&D push

Turns priority to future growth drivers and R&D investment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links